

P26461.A01

#3

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Katarzyna JURECZEK

Group Art Unit : Not Yet Assigned

Appl. No. : 10/518,386

(U.S. National Stage of PCT/PL02/000056)

Examiner : Not Yet Assigned

I.A. Filed : July 24, 2002

For : SUSTAINED RELEASE TABLET CONTAINING INDAPAMIDE

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Service Window, Mail Stop AMENDMENT  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir :

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98, Applicant hereby brings the following information to the attention of the Examiner in charge of the above-identified application, which includes information cited and discussed in the specification, the International Search Report, the International Preliminary Examination Report, and the Written Opinion issued in connection with International Patent Application No. PCT/PL02/000056, of which the present application is the U.S. National Stage Application. Copies of the International Search Report, the International Preliminary Examination Report, and the Written Opinion were enclosed with the papers when entering the National Stage on December 29, 2004. The Examiner is invited to review these materials to inspect the relevance indicated during

international examination with respect to the documents cited therein. The following is a list of the documents cited in the above-noted documents:

EP 0 519 820 B1 together with patent family member U.S. Patent No. 5,334,392. Applicants note that the European patent is cited on page 1 of the specification of the present application;

G. DAMIEN et al., Clinical Pharmacokinetics, Vol. 37, Suppl. 1, pp. 13-19, 1999;

GB 2 123 293 A;

DE 36 02 304 A1, together with patent family member GB 2 173 399 A; and

EP 1 057 479 A1.

Further to 37 C.F.R. §1.98 (a)(2)(ii), a copy of the U.S. patent is not enclosed herewith. However, if a copy is needed, the Examiner is respectfully requested to contact the undersigned.


Except for the U.S. patent, copies of the above-noted documents are enclosed together with a duly completed Form PTO-1449. The Examiner is accordingly requested to consider each of these documents, and to make them of record in this application by initialing in the appropriate spaces on the Form PTO-1449. Applicant respectfully requests that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

Applicant notes that an Office Action on the merits has not issued in the present application, and thus no fee is believed necessary to ensure

consideration of the submitted material. However, if an Office Action on the merits has issued and is crossing this statement in the mail, the undersigned hereby authorizes the Commissioner to charge any fee necessary for the consideration of this statement, including any payment under 37 C.F.R. §1.17 (p) to Deposit Account No. 19-0089.

Should there be any questions, the Examiner is invited to contact the undersigned at the below-listed telephone number.

Respectfully Submitted,  
Katarzyna JURECZEK



Neil F. Greenblum  
Reg. No. 28,394

Arnold Turk  
Reg. No. 33,094

May 2, 2005  
GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191

Group	Unknown
-------	---------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.